Volitionrx Limited · AMEX:VNRX
Volitionrx — Investor Presentation (September 2025)
10 slides from Volitionrx's investor presentation, September 2025
Slide 1: Corporate Deck
NYSE:VNRX Corporate Deck September 2025 Property of Volition© 2025 Slide 1
Slide 2: Forward Looking Statements and Disclaimer
Forward Looking Statements and Disclaimer Statements in this document may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncer
Slide 3: Executive Summary
Executive Summary Our mission is to save lives and improve outcomes for millions of people and animals worldwide. VolitionRx NYSE: VNRX Medical Devices IP Powerhouse Focus Licensing IP Cancer, Sepsis Low-cost testing Commercial Worldwide Animal $23M in licensing 1st $1M of Rev Large Unmet Needs Canc
Slide 4: Working at the Cutting Edge of Epigenetics
Working at the Cutting Edge of Epigenetics Measuring chromatin fragments Cancer NETs Global Experts in Quantifying Nucleosomes Data on file Property of Volition© 2025 Slide 4
Slide 5: Low-cost routine tests
Low-cost routine tests Platform agnostic; can be adapted to any diagnostic workflow Six 45 <10 6Hours hours 45 minutes <15 minute <10 minutes minutes <15 minutes minutes s Manual Automated Point of Care Lateral Flow Asset light - no need for own machines, labs or sales reps Property of Volition© 202
Slide 6: Commercialization Strategy
Commercialization Strategy Underlying principles: low capex, low opex business model focused on commercial partnerships and out- licensing R&D • R&D conducted by Volition and its research partners • Monetize IP through licensing agreements with: • upfront payments, • milestone payments, • recurring
Slide 7: Powered by Nu.Q
Powered by Nu.Q® 71 patents granted with coverage up to 2044 TAM Regulation Product Status Strategy Launched >$1Bn Non-Regulated Animal Testing Licensing Worldwide Cancer Clinical Sales & $4Bn Lab Developed Screening Validation Licensing $3Bn First sales Sales & CE Mark/ FDA Netosis ICU/ED in EU Lic
Slide 8: Projected Catalysts
Projected Catalysts Multiple licensing deals in 2025 and 2026 Catalyst 2025 2026 2027 Wellness plan adoption to drive sales ramp $5M milestone payment linked to use in felines Licensing cancer technology Adoption into national screening program(s) Licensing for Human NETosis / Sepsis Sales growth of
Slide 9: Volition Highlights
Volition Highlights Multiple products already launched Proven Licensing model, validated in Vet Strong IP Multiple multi billion TAM markets Low cost, scalable platform with high margins Asset light - no need for own machines, labs, or sales reps In confidential licensing discussions with 11 large d
Slide 10: Thank You!
Thank You! Property Strictly Confidential of Volition©| 2025 Not for Distribution | For Discussion Purposes Only Slide 10